Format

Send to:

Choose Destination
See comment in PubMed Commons below
Anticancer Res. 2014 May;34(5):2349-55.

Outcomes of patients with metastatic cervical cancer in a phase I clinical trials program.

Author information

  • 1Department of Investigational Cancer Therapeutics, Unit 0455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, U.S.A. siqingfu@mdanderson.org.

Abstract

BACKGROUND:

We evaluated clinical outcomes of patients with metastatic cervical cancer referred to a Phase I Clinical Trials Program.

PATIENTS AND METHODS:

We reviewed the electronic medical records of 54 consecutive phase I patients with metastatic cervical cancer over 6.5 years and analyzed the correlation between clinical outcome and potential predictors.

RESULTS:

All patients had received at least one systemic therapy for metastatic disease before referral. Only two patients declined phase I trial therapy. The median progression-free (PFS) and overall (OS) survivals were 3.6 and 10.6 months, respectively. Patients harboring phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA) mutations or phosphatase and tensin homolog loss, and those with more than two sites of metastasis who received more than one prior systemic chemotherapy before the referral had median PFS of 6.7 and 1.8 months, and median OS of 12.6 and 2.9 months, respectively.

CONCLUSION:

Patients with more than two metastatic sites who had received more than one prior system therapy had dismal outcomes. An aberrant PI3K pathway was frequently identified and associated with favorable outcome, providing a promising target.

KEYWORDS:

Cervical cancer; PIK3CA mutation; PTEN loss; outcome analysis; phase I trial

PMID:
24778042
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Write to the Help Desk